Tag: microbial contract biomanufacturing market
Microbial Contract Biomanufacturing Market is projected to be worth USD 9.3 billion by 2030
Thegrowing pipeline of biologics that can be produced in microbial systems, suchas antibody fragments and plasmid-based therapies, is anticipated to offerlucrative opportunities to service providers serving this niche, but growingmarket segment
The ‘‘Microbial Contract Biomanufacturing Market, 2020-2030’’ report
The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated.
Over 115 companies, across the world, claim to offer a variety of product development, manufacturing and support services, for various types of biologics that are manufactured / expressed in microbial systems, claims Roots An
Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly.
The microbial contract biomanufacturing market is projected grow at an annualized rate of 8.7%
Roots Analysis has done a detailed study on Microbial Contract Biomanufacturing Market, 2020-2030, covering key aspects of the industry and identifying potential future growth opportunities.
The microbial contract biomanufacturing market
The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated.
The microbial contract biomanufacturing market - Roots Analysis
Benefits offered by microbial biomanufacturing, such as low production costs and faster development timelines, have led many innovators to adopt these platforms for next generation biologics.
